Search the collection

Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 1
ArticlesPeer ReviewedFull Text
A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors
Author / Creator:Silk, Ann W ; Saraiya, Biren ; Groisberg, Roman ; Chan, Nancy ; Spencer, Kristen ; Girda, Eugenia ; Shih, Weichung ; Palmeri, Marisa ; Saunders, Tracie ; Berman, Robert M ; Coric, Vlad ; Chen, Suzie ; Zloza, Andrew ; Vieth, Joshua ; Mehnert, Janice M ; Malhotra, Jyoti
Publisher:London: BioMed Central Ltd
Journal title:European journal of medical research, 2022-07, Vol.27 (1), p.1-7, Article 107
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 2
ArticlesPeer ReviewedFull Text
Video-Based Kinematic Analysis of Movement Quality in a Phase 3 Clinical Trial of Troriluzole in Adults with Spinocerebellar Ataxia: A Post Hoc Analysis
Author / Creator:L’Italien, Gilbert J. ; Oikonomou, Evangelos K. ; Khera, Rohan ; Potashman, Michele H. ; Beiner, Melissa W. ; Maclaine, Grant D. H. ; Schmahmann, Jeremy D. ; Perlman, Susan ; Coric, Vladimir
Publisher:Cheshire: Springer Healthcare
Journal title:Neurology and therapy, 2024-08, Vol.13 (4), p.1287-1301
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 3
ArticlesPeer ReviewedFull Text
RIH researchers part of national study to evaluate drug Troriluzole to slow Alzheimer's disease progression
Publisher:Providence: Rhode Island Medical Society
Journal title:Medicine and health, Rhode Island, 2019-02, Vol.102 (1), p.74-74
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 4
ArticlesFull Text
FDA Accepts NDA Application for Troriluzole as Potential First Treatment for Spinocerebellar Ataxia
Author / Creator:Meglio, Marco
Publisher:Cranbury: Intellisphere, LLC
Journal title:Neurology live (Print), 2025-02
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 5
ArticlesFull Text
Biohaven to Submit NDA for Troriluzole for All Spinocerebellar Ataxia Forms Following Positive Phase 3 Data
Author / Creator:Meglio, Marco
Publisher:Cranbury: MultiMedia Healthcare Inc
Journal title:Neurology live (Print), 2024-09
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 6
ArticlesFull Text
Biohaven Submits New Drug Application for Troriluzole as Spinocerebellar Ataxia Type 3 Therapy
Author / Creator:Meglio, Marco
Publisher:Cranbury: Intellisphere, LLC
Journal title:Neurology live (Print), 2023-06
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 7
ArticlesFull Text
Utilizing the SCACOMS Composite Measure to Assess Treatment Benefit of Troriluzole in Spinocerebellar Ataxia: Irfan Qureshi, MD
Author / Creator:Qureshi, Irfan
Publisher:Cranbury: Intellisphere, LLC
Journal title:Neurology live (Print), 2024-04
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 8
ArticlesFull Text
NDA Accepted for Troriluzole, FDA Approves Mirdametinib for Neurofibromatosis, New Tablet Formulation for Risdiplam Approved
Publisher:Cranbury: Intellisphere, LLC
Journal title:Neurology live (Print), 2025-02
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 9
ArticlesFull Text
Troriluzole Not Effective for Symptomatic Treatment of Alzheimer Disease
Author / Creator:Johnson, Victoria
Publisher:Cranbury: MultiMedia Healthcare Inc
Journal title:Neurology live (Print), 2021-01
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 10
ArticlesFull Text
Troriluzole Shows Promise in Spinocerebellar Ataxia Type 3 Subgroup Despite Failing to Achieve Primary End Point
Author / Creator:Meglio, Marco
Publisher:Cranbury: MultiMedia Healthcare Inc
Journal title:Neurology live (Print), 2022-05
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 11
Newsletter articlesFull Text
Biohaven secures FDA priority review for troriluzole in spinocerebellar ataxia
Publisher:London: Normans Media Ltd
Journal title:M2 EquityBites, 2025
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 12
Newsletter articlesFull Text
Biohaven Gets FDA Priority Review of Troriluzole for Spinocerebellar Ataxia
Publisher:New York: Dow Jones & Company Inc
Journal title:Dow Jones Institutional News, 2025
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 13
Newsletter articlesFull Text
Biohaven secures FDA priority review for troriluzole in spinocerebellar ataxia
Publisher:London: Normans Media Ltd
Journal title:M2 Pharma, 2025
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 14
ArticlesFull Text
Gene Therapy AMT-130 in Huntington Disease, NDA Submitted for Troriluzole in Spinocerebellar Ataxia, FDA Clears Alzheimer Assays
Publisher:Cranbury: Intellisphere, LLC
Journal title:Neurology live (Print), 2023-07
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 15
Newsletter articlesFull Text
Biohaven Shares Rise 20% After Troriluzole Slows Decline in Study
Publisher:New York: Dow Jones & Company Inc
Journal title:Dow Jones Institutional News, 2024
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 16
Newsletter articlesFull Text
Biohaven Sees Positive Results From Troriluzole Study for Spinocerebellar Ataxia
Publisher:New York: Dow Jones & Company Inc
Journal title:Dow Jones Institutional News, 2024
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 17
Newsletter articlesFull Text
Biohaven Announces 3-Year Results for Troriluzole in Spinocerebellar Ataxia Treatment
Publisher:Southfield: Accretive Capital LLC d/b/a Benzinga
Journal title:Benzinga Newswires, 2024
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 18
Newsletter articlesFull Text
Clinical Trial: Troriluzole Individual Patient IND Expanded Access Program
Publisher:Washington, D.C: HT Digital Streams Limited
Journal title:US Fed News Service, Including US State News, 2023
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 19
Newsletter articlesFull Text
Biohaven Told That FDA Won't Review NDA Application for Troriluzole
Publisher:New York: Dow Jones & Company Inc
Journal title:Dow Jones Institutional News, 2023
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 20
Web ResourcesFull Text
GuruFocus.com: Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for
Publisher:Chatham: Newstex
Journal title:Newstex Finance & Accounting Blogs, 2025
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.

Showing 1 to 20 of 97 results

Export record to excel

Export this record

Export record to excel

A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors

Export this record

Export record to excel

Video-Based Kinematic Analysis of Movement Quality in a Phase 3 Clinical Trial of Troriluzole in Adults with Spinocerebellar Ataxia: A Post Hoc Analysis

Export this record

Export record to excel

RIH researchers part of national study to evaluate drug Troriluzole to slow Alzheimer's disease progression

Export this record

Export record to excel

FDA Accepts NDA Application for Troriluzole as Potential First Treatment for Spinocerebellar Ataxia

Export this record

Export record to excel

Biohaven to Submit NDA for Troriluzole for All Spinocerebellar Ataxia Forms Following Positive Phase 3 Data

Export this record

Export record to excel

Biohaven Submits New Drug Application for Troriluzole as Spinocerebellar Ataxia Type 3 Therapy

Export this record

Export record to excel

Utilizing the SCACOMS Composite Measure to Assess Treatment Benefit of Troriluzole in Spinocerebellar Ataxia: Irfan Qureshi, MD

Export this record

Export record to excel

NDA Accepted for Troriluzole, FDA Approves Mirdametinib for Neurofibromatosis, New Tablet Formulation for Risdiplam Approved

Export this record

Export record to excel

Troriluzole Not Effective for Symptomatic Treatment of Alzheimer Disease

Export this record

Export record to excel

Troriluzole Shows Promise in Spinocerebellar Ataxia Type 3 Subgroup Despite Failing to Achieve Primary End Point

Export this record

Export record to excel

Biohaven secures FDA priority review for troriluzole in spinocerebellar ataxia

Export this record

Export record to excel

Biohaven Gets FDA Priority Review of Troriluzole for Spinocerebellar Ataxia

Export this record

Export record to excel

Biohaven secures FDA priority review for troriluzole in spinocerebellar ataxia

Export this record

Export record to excel

Gene Therapy AMT-130 in Huntington Disease, NDA Submitted for Troriluzole in Spinocerebellar Ataxia, FDA Clears Alzheimer Assays

Export this record

Export record to excel

Biohaven Shares Rise 20% After Troriluzole Slows Decline in Study

Export this record

Export record to excel

Biohaven Sees Positive Results From Troriluzole Study for Spinocerebellar Ataxia

Export this record

Export record to excel

Biohaven Announces 3-Year Results for Troriluzole in Spinocerebellar Ataxia Treatment

Export this record

Export record to excel

Clinical Trial: Troriluzole Individual Patient IND Expanded Access Program

Export this record

Export record to excel

Biohaven Told That FDA Won't Review NDA Application for Troriluzole

Export this record

Export record to excel

GuruFocus.com: Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for

Refine your search